Mesenchymal stem cells and uses therefor

Abstract

The present technology provides compositions of mesenchymal stem cells for promoting wound healing or fracture healing and methods of promoting wound healing or fracture healing comprising the steps of administering mesenchymal stem cells in an effective amount.

1 . A composition comprising allogeneic mesenchymal stem cells in an amount effective to promote wound healing in a human, wherein the composition is administered directly to the wound. 
     
     
         2 . The composition of  claim 1 , wherein the wound is an external or internal wound. 
     
     
         3 . The composition of  claim 1 , wherein the wound is a bone fracture. 
     
     
         4 . The composition of  claim 2 , wherein the wound is an ulcer. 
     
     
         5 . The composition of  claim 4 , wherein the ulcer is a dermal ulcer selected from the group consisting of dermal ulcers found in the feet, hands, legs and arms. 
     
     
         6 . The composition of  claim 5 , wherein the dermal ulcers are caused by diseases selected from the group consisting of diabetes and sickle cell anemia. 
     
     
         7 . The composition of  claim 1 , wherein the mesenchymal stem cells are not genetically manipulated. 
     
     
         8 . The composition of  claim 1 , wherein the mesenchymal stem cells wherein the mesenchymal stem cells induce the secretion of a factor selected from the group consisting of prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF), growth hormone, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and endothelin-1. 
     
     
         9 . The composition of  claim 1 , wherein the mesenchymal stem cells express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         10 . The composition of  claim 1 , wherein the mesenchymal stem cells bind to an antibody selected from the group consisting of an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, and an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745. 
     
     
         11 . The composition of  claim 1 , wherein the mesenchymal stem cells are administered to the wound using a dressing or reservoir containing the mesenchymal stem cells. 
     
     
         12 . The composition of  claim 1 , wherein the mesenchymal stem cells are administered to the wound using a soluble carrier or solid matrix. 
     
     
         13 . The composition of  claim 1 , wherein the mesenchymal stem cells are administered to the wound in a liquid or cell suspension. 
     
     
         14 . A method of promoting wound healing or fracture healing in a human patient comprising the steps of administering a composition comprising mesenchymal stem cells in an amount effective to promote wound healing or fracture healing in a human. 
     
     
         15 . The method of  claim 14 , wherein the mesenchymal stem cells are administered directly to the wound or fracture. 
     
     
         16 . The method of  claim 14 , wherein the wound is an external or internal wound. 
     
     
         17 . The method of  claim 14 , wherein the wound is a dermal ulcer selected from the group consisting of dermal ulcers found in the feet, hands, legs or arms. 
     
     
         18 . The method of  claim 17 , wherein the dermal ulcer is caused by a disease selected from the group consisting of diabetes and sickle cell anemia. 
     
     
         19 . The method of  claim 14 , wherein the mesenchymal stem cell are not genetically manipulated. 
     
     
         20 . The method of  claim 14 , wherein the mesenchymal stem cells induce the secretion of a factor selected from the group consisting of prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF), growth hormone, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and endothelin-1. 
     
     
         21 . The method of  claim 14 , wherein the mesenchymal stem cells are administered to the wound using a dressing or reservoir containing the mesenchymal stem cells. 
     
     
         22 . The method of  claim 14 , wherein the mesenchymal stem cells are administered to the wound using a soluble carrier or a solid matrix. 
     
     
         23 . The method of  claim 14 , wherein the mesenchymal stem cells are administered in a liquid or cell suspension. 
     
     
         24 . The method of  claim 14 , wherein the mesenchymal stem cells promote the secretion of interleukin-10 and interleukin-4. 
     
     
         25 . The method of  claim 14 , wherein the mesenchymal stem cells express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         26 . The method of  claim 14 , wherein the mesenchymal stem cells bind to an antibody selected from the group consisting of an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, and an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745.